Potential role of dipeptidyl peptidase-4 inhibitors in atrial fibrillation

International Journal of Cardiology

Volumn 207, Issue , 2016, Pages 46-47

  Zhang, Xiaowei ^a   Zhang, Zhiwei ^a   Li, Mingzhen ^b   Li, Guangping ^a   Liu, Tong ^a  

^a SECOND HOSPITAL OF TIANJIN MEDICAL UNIVERSITY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Atrial fibrillation; Atrial remodeling; Dipeptidyl peptidase 4 inhibitors; Inflammation; Oxidative stress

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; HYDROGEN PEROXIDE; LINAGLIPTIN; REACTIVE OXYGEN METABOLITE; SITAGLIPTIN; TRANSFORMING GROWTH FACTOR BETA1;

ANTIARRHYTHMIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATRIAL FIBRILLATION; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DIABETIC PATIENT; HEART MUSCLE FIBROSIS; HEART PROTECTION; HUMAN; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; ANIMAL; METABOLISM;

ANIMALS; ATRIAL FIBRILLATION; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS;

EID: 84957938318     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.01.123     Document Type: Article

References (32)

1. G.P. Fadini, and A. Avogaro Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1 Vasc. Pharmacol. 55 2011 10 16
2. K. Fukui, H. Kawahito, N. Wakana, M. Kikai, K. Terada, K. Yamamoto, and et al. Dipeptidyl peptidase-4 inhibitor sitagliptin improves pancreatic beta-cell function in hypertensive diabetic patients treated with angiotensin receptor blockers J. Renin-Angiotensin-Aldosterone Syst. 16 2015 1001 1009
3. R. Ito, T. Fukui, T. Hayashi, A. Osamura, M. Ohara, N. Hara, and et al. Teneligliptin, a dipeptidyl peptidase-4 inhibitor, improves early-phase insulin secretion in drug-naive patients with type 2 diabetes Drugs R&D 15 2015 245 251
4. D. Rohrborn, N. Wronkowitz, and J. Eckel DPP4 in diabetes Front. Immunol. 6 2015 386
5. M. Sauve, K. Ban, M.A. Momen, Y.Q. Zhou, R.M. Henkelman, M. Husain, and et al. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice Diabetes 59 2010 1063 1073
6. B. Hocher, Y. Sharkovska, M. Mark, T. Klein, and T. Pfab The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats Int. J. Cardiol. 167 2013 87 93
7. Q. Gong, S. Rajagopalan, and J. Zhong Dpp4 inhibition as a therapeutic strategy in cardiometabolic disease: Incretin-dependent and -independent function Int. J. Cardiol. 197 2015 170 179
8. M. Ihara, H. Asanuma, S. Yamazaki, H. Kato, Y. Asano, Y. Shinozaki, and et al. An interaction between glucagon-like peptide-1 and adenosine contributes to cardioprotection of a dipeptidyl peptidase 4 inhibitor from myocardial ischemia-reperfusion injury Am. J. Physiol. Heart Circ. Physiol. 308 2015 H1287 H1297
9. Z. Shah, C. Pineda, T. Kampfrath, A. Maiseyeu, Z. Ying, I. Racoma, and et al. Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways Vasc. Pharmacol. 55 2011 2 9
10. K. Chinda, S. Palee, S. Surinkaew, M. Phornphutkul, S. Chattipakorn, and N. Chattipakorn Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury Int. J. Cardiol. 167 2013 451 457
11. X. Hu, X. Yang, and H. Jiang Glucagon-like peptide-1 and related agents: Novel anti-arrhythmic agents during myocardial ischemia and reperfusion Int. J. Cardiol. 168 2013 3119 3120
12. T. Yamamoto, M. Shimano, Y. Inden, M. Takefuji, S. Yanagisawa, N. Yoshida, and et al. Alogliptin, a dipeptidyl peptidase-4 inhibitor, regulates the atrial arrhythmogenic substrate in rabbits Heart Rhythm. 12 2015 1362 1369
13. T. Liu, G. Li, L. Li, and P. Korantzopoulos Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: A meta-analysis J. Am. Coll. Cardiol. 49 2007 1642 1648
14. L.H. Zheng, Y. Yao, L.M. Wu, K.J. Zhang, and S. Zhang Relationships of high-sensitive C-reactive protein and P-wave dispersion in lone atrial fibrillation Chin. Med. J. 128 2015 1450 1454
15. A. Aroor, S. McKarns, R. Nistala, V. Demarco, M. Gardner, M. Garcia-Touza, and et al. DPP-4 inhibitors as therapeutic modulators of immune cell function and associated cardiovascular and renal insulin resistance in obesity and diabetes Cardiorenal Med. 3 2013 48 56
16. A.J. Tremblay, B. Lamarche, C.F. Deacon, S.J. Weisnagel, and P. Couture Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes Metabolism 63 2014 1141 1148
17. Y. Nakamura, M. Tsuji, H. Hasegawa, K. Kimura, K. Fujita, M. Inoue, and et al. Anti-inflammatory effects of linagliptin in hemodialysis patients with diabetes Hemodial. Int. 18 2014 433 442
18. B. Bostick, J. Habibi, L. Ma, A. Aroor, N. Rehmer, M.R. Hayden, and et al. Dipeptidyl peptidase inhibition prevents diastolic dysfunction and reduces myocardial fibrosis in a mouse model of western diet induced obesity Metabolism 63 2014 1000 1011
19. T. Liu, Q. Shao, S. Miao, E. Liu, G. Xu, R. Yuan, and et al. Red cell distribution width as a novel, inexpensive marker for paroxysmal atrial fibrillation Int. J. Cardiol. 171 2014 e52 e53
20. T. Liu, H. Zhao, J. Li, P. Korantzopoulos, and G. Li Rosiglitazone attenuates atrial structural remodeling and atrial fibrillation promotion in alloxan-induced diabetic rabbits Cardiovasc. Ther. 32 2014 178 183
21. Z. Zhao, T. Liu, J. Li, W. Yang, E. Liu, and G. Li Elevated red cell distribution width level is associated with oxidative stress and inflammation in a canine model of rapid atrial pacing Int. J. Cardiol. 174 2014 174 176
22. T. Liu, Q. Shao, P. Korantzopoulos, E. Liu, G. Xu, and G. Li Serum levels of nicotinamide-adenine dinucleotide phosphate oxidase 4 are associated with non-valvular atrial fibrillation Biomed. Rep. 3 2015 864 868
23. M.M. Polovina, M.C. Ostojic, and T.S. Potpara Relation of biomarkers of inflammation and oxidative stress with hypertension occurrence in lone atrial fibrillation Mediat. Inflamm. 2015 2015 653026
24. T. Liu, P. Korantzopoulos, and G. Li Antioxidant therapies for the management of atrial fibrillation Cardiovasc. Diagn. Ther. 2 2012 298 307
25. R. Rodrigo, P. Korantzopoulos, M. Cereceda, R. Asenjo, J. Zamorano, E. Villalabeitia, and et al. A randomized controlled trial to prevent post-operative atrial fibrillation by antioxidant reinforcement J. Am. Coll. Cardiol. 62 2013 1457 1465
26. F. Violi, D. Pastori, P. Pignatelli, and L. Loffredo Antioxidants for prevention of atrial fibrillation: A potentially useful future therapeutic approach? A review of the literature and meta-analysis Europace 16 2014 1107 1116
27. H. Fu, G. Li, C. Liu, J. Li, X. Wang, L. Cheng, and et al. Probucol prevents atrial remodeling by inhibiting oxidative stress and TNF-alpha/NF-kappaB/TGF-beta signal transduction pathway in alloxan-induced diabetic rabbits J. Cardiovasc. Electrophysiol. 26 2015 211 222
28. 2 induced oxidative stress in isolated cardiomyocytes PLoS One 8 2013 e54518
29. S. Ravassa, J. Beaumont, A. Huerta, J. Barba, I. Coma-Canella, A. Gonzalez, and et al. Association of low GLP-1 with oxidative stress is related to cardiac disease and outcome in patients with type 2 diabetes mellitus: A pilot study Free Radic. Biol. Med. 81 2015 1 12
30. M. Lenski, A. Kazakov, N. Marx, M. Bohm, and U. Laufs Effects of DPP-4 inhibition on cardiac metabolism and function in mice J. Mol. Cell. Cardiol. 51 2011 906 918
31. W.B. White, C.P. Cannon, S.R. Heller, S.E. Nissen, R.M. Bergenstal, G.L. Bakris, and et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes N. Engl. J. Med. 369 2013 1327 1335
32. J. Spinar, and A. Smahelova SAVOR TIMI 53 - saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus Vnitr. Lek. 59 2013 1003 1007